Johnson & Johnson ($JNJ) announced that it is being investigated by the Justice Department with regard to its services to a pair of arthritis drugs. Its co-payment support programs are also being looked into by the U.S. Attorney's office in Massachusetts. The support programs being probed are related to hepatitis C drug Olysiotm and Simponi and Crohn's disease drug Stelara.
PTC Therapeutics ($PTCT) announced that it will receive a net price of $35k per year per patient for Emflaza, the Duchenne muscular dystrophy drug. The company had acquired the drug from Marathon Pharmaceuticals, which had announced a wholesale list price of $89K annually for the drug after it was approved by the FDA in February.